[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 23.23.50.247. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Correspondence
September 15, 2008

Pimecrolimus: A Novel Treatment for Cetuximab-Induced Papulopustular Eruption

Arch Dermatol. 2008;144(9):1236-1238. doi:10.1001/archderm.144.9.1236

Cancer treatment via epidermal growth factor receptor (EGFR)–targeted therapies has been used increasingly over the last years owing to their lower overall toxic effect profile and higher therapeutic efficacy than conventional cytotoxic drugs.1 Approximately two-thirds of patients treated with EGFR inhibitors (EGFRIs) develop skin reactions.2 However, since the skin reactions appear to be associated with a better response rate to EGFRI treatment and a better overall survival rate,1,2 continuation of treatment despite the cutaneous adverse effects is recommended and important. As the cause of the skin changes is still unclear, no cause-based treatment options exist.

First Page Preview View Large
First page PDF preview
First page PDF preview
×